



Prior Authorization Request

TAGRISSE (osimertinib)

Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A – Patient

Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:		Province:	Postal Code:
Email address:			
Telephone (home):		Telephone (cell):	Telephone (work):

Coordination of benefits

Patient Assistance Program	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Fax: _____
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>
Primary Coverage	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <i>*Attach decision letter*</i>

Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Plan Member Signature

Date



Prior Authorization Request

TAGRISSO (osimertinib)

Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do not provide genetic test information or results.

SECTION 1 – DRUG REQUESTED

TAGRISSO (osimertinib)				<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request*
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration		
Site of drug administration:					
<input type="checkbox"/> Home	<input type="checkbox"/> Physician's office/Infusion clinic	<input type="checkbox"/> Hospital (outpatient)	<input type="checkbox"/> Hospital (inpatient)		

* Please submit proof of prior coverage if available

SECTION 2 – ELIGIBILITY CRITERIA

1. Please indicate if the patient satisfies the below criteria:

Non-Small Cell Lung Cancer – EGFR Mutation, Adjuvant

- For the adjuvant treatment of stage IB-IIIa non-small cell lung cancer (NSCLC) with tumours that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, in an adult, AND
- The patient has undergone tumour resection, AND
- The patient has not undergone radiation therapy

Non-Small Cell Lung Cancer – EGFR Mutation, Locally Advanced

- For the treatment of locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) with tumours that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations in an adult, AND
- The patient has not progressed during or following platinum based chemoradiation therapy

Non-Small Cell Lung Cancer – EGFR Mutation, First-Line

- For the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with tumours that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (alone or in combination with other EGFR mutations), in an adult, AND
- The patient has not received prior systemic therapy, AND
- TAGRISSO will be used in combination with pemetrexed and platinum-based chemotherapy, OR
- TAGRISSO will be used as monotherapy

Non-Small Cell Lung Cancer – EGFR T790M Mutation-Positive

- For the treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) in an adult, AND
- The patient has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy (*Please list prior therapies in the chart below*)



Prior Authorization Request

TAGRISO (osimertinib)

OR

None of the above criteria applies.

Relevant additional information:

2. Please list previously tried therapies

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	To	Inadequate response	Allergy/ Intolerance
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>

SECTION 3 – PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

Please fax or mail the completed form to Express Scripts Canada®

Fax: Express Scripts Canada Clinical Services
1 (855) 712-6329

Mail: Express Scripts Canada Clinical Services
6985 Financial Drive, Suite 300
Mississauga, ON, L5N 0G3